Press release
Liver Cirrhosis Clinical Trial Pipeline Shows Potential with Active Contributions from 30+ Key Companies | DelveInsight
Download DelveInsight's comprehensive Liver Cirrhosis Pipeline Report to explore emerging therapies, key Companies, and future treatment landscapes @ https://www.delveinsight.com/sample-request/liver-cirrhosis-pipeline-insight [https://www.delveinsight.com/sample-request/liver-cirrhosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Liver Cirrhosis Pipeline Report
* On January 23, 2026- Boehringer Ingelheim conducted a study is to find out the effect of survodutide on MASH and liver fibrosis. The purpose of the second part is to find out how safe and effective survodutide is in improving liver function. Participants are put into 2 groups randomly, which means by chance. 1 group gets survodutide and 1 group gets placebo. Placebo looks like survodutide but does not contain any medicine. Each participant has twice the chance of getting survodutide. Participants and doctors do not know who is in which group. Participants inject survodutide or placebo under their skin once a week. The survodutide doses are slowly increased until the target dose is reached. All participants receive counselling to make changes to their diet and to exercise regularly.
* On January 21, 2026- Ipsen announced a study will have confirmed Primary Biliary Cholangitis (PBC) with inadequate response or intolerance to ursodeoxycholic acid (which is a medication used in the management and treatment of cholestatic liver disease).
* On January 20, 2026- AstraZeneca conducted a study is designed to evaluate the safety of zibotentan/dapagliflozin in combination as compared to zibotentan monotherapy as well as zibotentan/dapagliflozin in combination and zibotentan monotherapy as compared to placebo in patients with cirrhosis with or without a history of decompensation. The study will be conducted in approximately 52 study centers in North America, Asia and Europe.
* DelveInsight's Liver Cirrhosis pipeline report depicts a robust space with 30+ active players working to develop 30+ pipeline therapies for Liver Cirrhosis treatment.
* The leading Liver Cirrhosis Companies such as Versantis AG, Mirum Pharmaceuticals, Sagimet Biosciences, TenNor Therapeutics, Prism Pharma, Vedanta Biosciences, Lipocine, Gwo Xi Stem Cell Applied Technology, Galectin Therapeutics, Resolution Therapeutics, Ipsen, and AstraZeneca and others.
* Promising Liver Cirrhosis Therapies such as IDN-6556, AZD2389, Resmetirom, GI262570 0.5 mg, Rifaximin SSD 40 mg IR tablet, NRL972, BMS-986263 and others.
Access DelveInsight's in-depth Liver Cirrhosis Pipeline Analysis for a closer look at promising breakthroughs @ Liver Cirrhosis Clinical Trials and Studies [https://www.delveinsight.com/sample-request/liver-cirrhosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Liver Cirrhosis Emerging Drugs Profile
* Elafibranor: Ipsen
Elafibranor (GFT-505) is under development for the treatment of colitis, non-alcoholic fatty liver disease, primary biliary cholangitis (PBC), and primary sclerosing cholangitis. The drug candidate is administered orally as a coated tablet. It acts by targeting peroxisome proliferator-activated receptor (PPAR) alpha and PPAR-beta / PPAR- delta. The drug candidate was under development for dyslipidemia, abdominal obesity, type 2 diabetes, Crohn's disease, insulin resistance and glucose intolerance, colitis and NAFLD/NASH-induced hepatocellular carcinoma (HCC). Currently, the drug is in phase III stage of its clinical trial.
* AZD2389: AstraZeneca
AZD2389 is a hepatoprotectant small molecule developed by AstraZeneca. It is designed to provide protection to the liver. The drug is part of a class aimed at treating liver-related diseases or conditions. Currently, the drug is in Phase II stage of its clinical trial for the treatment of liver Cirrhosis.
* PHIN-214: PharmaIN
PHIN-214 is an investigational drug currently undergoing Phase Ib safety trials by harmaIN, aimed at treating refractory ascites, a condition for which no FDA-approved pharmacological therapy currently exists. Its mechanism of action (MOA) involves targeting and shutting down the Renin-Angiotensin-Aldosterone System (RAAS) signaling pathway, which plays a key role in the retention of excess salt and water by the kidneys. By inhibiting this pathway, PHIN-214 seeks to prevent the accumulation of ascitic fluid, offering potential therapeutic benefits for patients with liver disease who no longer respond to diuretic treatments.
The Liver Cirrhosis pipeline report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Liver Cirrhosis with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Liver Cirrhosis Treatment.
* Liver Cirrhosis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Liver Cirrhosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Liver Cirrhosis market.
Explore DelveInsight's expert-driven report today! @ Liver Cirrhosis Unmet Needs [https://www.delveinsight.com/sample-request/liver-cirrhosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Liver Cirrhosis Companies
Versantis AG, Mirum Pharmaceuticals, Sagimet Biosciences, TenNor Therapeutics, Prism Pharma, Vedanta Biosciences, Lipocine, Gwo Xi Stem Cell Applied Technology, Galectin Therapeutics, Resolution Therapeutics, Ipsen, and AstraZeneca and others.
Liver Cirrhosis Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal
Liver Cirrhosis Products have been categorized under various Molecule types such as
* Oligonucleotide
* Peptide
* Small molecule
Download DelveInsight's latest report to gain strategic insights into upcoming Therapies and key Developments @ Liver Cirrhosis Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/liver-cirrhosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Liver Cirrhosis Pipeline Report
* Coverage- Global
* Liver Cirrhosis Companies- Versantis AG, Mirum Pharmaceuticals, Sagimet Biosciences, TenNor Therapeutics, Prism Pharma, Vedanta Biosciences, Lipocine, Gwo Xi Stem Cell Applied Technology, Galectin Therapeutics, Resolution Therapeutics, Ipsen, and AstraZeneca and others.
* Liver Cirrhosis Therapies- IDN-6556, AZD2389, Resmetirom, GI262570 0.5 mg, Rifaximin SSD 40 mg IR tablet, NRL972, BMS-986263 and others.
* Liver Cirrhosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Liver Cirrhosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Find out in DelveInsight's exclusive Liver Cirrhosis Pipeline Report-access it now! @ Liver Cirrhosis Emerging Drugs and Major Companies [https://www.delveinsight.com/sample-request/liver-cirrhosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Liver Cirrhosis: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Liver Cirrhosis - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Elafibranor: Ipsen
* Mid Stage Products (Phase II)
* Volixibat: Mirum Pharmaceuticals
* Early Stage Products (Phase I)
* Mid Stage Products (Phase II)
* Preclinical Stage Products
* PVT201: Parvus Therapeutics
* Inactive Products
* Liver Cirrhosis - Collaborations Assessment- Licensing / Partnering / Funding
* Liver Cirrhosis - Unmet Needs
* Liver Cirrhosis - Market Drivers and Barriers
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=liver-cirrhosis-clinical-trial-pipeline-shows-potential-with-active-contributions-from-30-key-companies-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/liver-cirrhosis-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Liver Cirrhosis Clinical Trial Pipeline Shows Potential with Active Contributions from 30+ Key Companies | DelveInsight here
News-ID: 4374110 • Views: …
More Releases from ABNewswire
Relapsing-Remitting Multiple Sclerosis Clinical Trial Pipeline Accelerates as 20 …
DelveInsight's, "Relapsing-Remitting Multiple Sclerosis Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Relapsing-Remitting Multiple Sclerosis pipeline landscape. It covers the Relapsing-Remitting Multiple Sclerosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Relapsing-Remitting Multiple Sclerosis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Download DelveInsight's comprehensive…
Oncolytic Virus Clinical Trial Pipeline Gains Momentum: 120+ Companies Lead the …
DelveInsight's, "Oncolytic Virus Cancer Therapy Pipeline Insight 2025" report provides comprehensive insights about 120+ companies and 125+ pipeline drugs in Oncolytic Virus Cancer Therapy pipeline landscape. It covers the Oncolytic Virus Cancer Therapy pipeline drug profiles, including clinical and non-clinical stage products. It also covers the Oncolytic Virus Cancer Therapy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products…
Dr. Jeffrey Tauth Reaffirms Commitment to Cardiovascular Excellence and Patient …
Hot Springs, Arkansas - February 2, 2026 - Dr. Jeffrey G. Tauth, M.D., F.A.C.C., a cornerstone of the Arkansas medical community for over 30 years, today announced a renewed focus on expanding patient education and preventive heart health initiatives within the Hot Springs region. As a board-certified interventional cardiologist, Dr. Tauth continues his mission to provide high-quality, evidence-based cardiovascular care to the patients he has served for three decades.
Image: https://www.abnewswire.com/upload/2026/02/4bd0202ea63a6076ba5ea1546f9d5941.jpg
Dr.…
Giliarto Expands Its Focus on Custom Engagement Rings Built Around Gemstones
Giliarto announces an expanded focus on custom engagement rings, emphasizing natural gemstones, thoughtful design, and craftsmanship built for long-term wear. Each ring is developed through a structured, collaborative process that prioritizes material integrity and individuality over mass-produced jewelry.
Giliarto announces an expanded focus on custom engagement rings, responding to growing demand for engagement jewelry that prioritizes individuality, material integrity, and long-term design value over standardized, mass-produced solutions.
Rather than offering fixed templates,…
More Releases for Cirrhosis
Cirrhosis Pipeline: Novel Antifibrotic Therapies and Regenerative Approaches Red …
The treatment landscape for cirrhosis, a progressive liver condition marked by fibrosis and compromised liver function, is witnessing a transformative shift as biopharmaceutical companies advance beyond symptomatic management to target the underlying causes of liver damage. With no approved therapies to reverse established fibrosis, there is a growing focus on antifibrotic agents, hepatoprotective compounds, and regenerative therapies that aim to halt or reverse disease progression. Companies like Ocera Therapeutics, Gilead…
Liver Cirrhosis - Drug Pipeline Landscape, 2023
Cirrhosis, also known as liver cirrhosis or hepatic cirrhosis and end-stage liver disease, is a condition characterised by impaired liver function caused by the formation of scar tissue known as fibrosis as a result of liver disease damage. Cirrhosis is caused by alcoholic liver disease, non-alcoholic steatohepatitis (NASH), chronic hepatitis B, and chronic hepatitis C.
To Remain 'Ahead' Of Your Competitors, Request for A Sample: https://www.globalinsightservices.com/request-sample/GIS31149
Cirrhosis symptoms emerge slowly until liver…
Primary Biliary Cirrhosis - Drug Pipeline Landscape, 2023
New York, Global Insight Services have recently published a report on Primary Biliary Cirrhosis - Drug Pipeline Landscape. The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration.
Read more about Primary Biliary Cirrhosis - Drug Pipeline here: https://www.globalinsightservices.com/reports/primary-biliary-cirrhosis-primary-biliary-cholangitis-drug-pipeline-landscape-2022/
Primary Biliary Cirrhosis (Primary Biliary Cholangitis) is a chronic disease in which the small bile ducts in the liver become injured and inflamed…
Liver Cirrhosis - Drug Pipeline Landscape, 2023
New York, Global Insight Services have recently published a report on Liver Cirrhosis - Drug Pipeline Landscape. The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration.
Read more about this report: https://www.globalinsightservices.com/reports/liver-cirrhosis-drug-pipeline-landscape-2023/
Cirrhosis, also known as liver cirrhosis or hepatic cirrhosis and end-stage liver disease, is a condition characterised by impaired liver function caused by the formation of scar tissue known…
Primary Biliary Cirrhosis - Drug Pipeline Landscape, 2022
Global Insight Services have recently published a report on Primary Biliary Cirrhosis - Drug Pipeline Landscape. The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration.
Primary Biliary Cirrhosis (Primary Biliary Cholangitis) is a chronic disease in which the small bile ducts in the liver become injured and inflamed and are destroyed eventually.
Read more about Primary Biliary Cirrhosis - Drug Pipeline…
Global Liver Cirrhosis Market Growth 2018-2023
Market Research Report Store offers a latest published report on Liver Cirrhosis Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. This report focuses on the key global Liver Cirrhosis players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.To analyze the Liver Cirrhosis with respect to individual…
